These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33837670)

  • 21. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology.
    Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A
    Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased atherogenic lipoprotein profile in children with non-alcoholic steatohepatitis.
    Castillo-Leon E; Connelly MA; Konomi JV; Caltharp S; Cleeton R; Vos MB
    Pediatr Obes; 2020 Sep; 15(9):e12648. PubMed ID: 32367624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism.
    Musso G; Cassader M; De Michieli F; Rosina F; Orlandi F; Gambino R
    Hepatology; 2012 Sep; 56(3):933-42. PubMed ID: 22684858
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hypolipidemic therapy in patients with non-alcoholic fatty liver disease].
    Zvenigorodskaia LA; Samsonova NG; Mel'nikova NV; Cherkashova EA
    Eksp Klin Gastroenterol; 2010; (7):25-33. PubMed ID: 21033080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.
    Chiriac S; Stanciu C; Girleanu I; Cojocariu C; Sfarti C; Singeap AM; Cuciureanu T; Huiban L; Muzica CM; Zenovia S; Nastasa R; Trifan A
    Can J Gastroenterol Hepatol; 2021; 2021():6696857. PubMed ID: 33505944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis.
    Arca M; Pigna G; Favoccia C
    Curr Vasc Pharmacol; 2012 Nov; 10(6):684-6. PubMed ID: 23259553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Screening of Cardiovascular Disease in Nonalcoholic Fatty Liver Disease: Whom and How?
    Choudhary NS; Duseja A
    J Clin Exp Hepatol; 2019; 9(4):506-514. PubMed ID: 31516267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.
    VanWagner LB; Lapin B; Skaro AI; Lloyd-Jones DM; Rinella ME
    Liver Int; 2015 Dec; 35(12):2575-83. PubMed ID: 25977117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular morbidity and mortality after liver transplantation: The protective role of mycophenolate mofetil.
    D'Avola D; Cuervas-Mons V; Martí J; Ortiz de Urbina J; Lladó L; Jimenez C; Otero E; Suarez F; Rodrigo JM; Gómez MA; Fraga E; Lopez P; Serrano MT; Rios A; Fábrega E; Herrero JI
    Liver Transpl; 2017 Apr; 23(4):498-509. PubMed ID: 28160394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart.
    Dogru T; Kirik A; Gurel H; Rizvi AA; Rizzo M; Sonmez A
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonalcoholic Steatohepatitis After Liver Transplantation.
    Cotter TG; Charlton M
    Liver Transpl; 2020 Jan; 26(1):141-159. PubMed ID: 31610081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
    Sahebkar A; Chew GT; Watts GF
    Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Relationship Between Hypoadiponectinemia and Cardiovascular Events in Liver Transplant Recipients.
    Siddiqui MB; Patel S; Arshad T; Lee E; Albhaisi S; Driscoll C; Wolver S; Reichman T; Bhati C; Siddiqui MS
    Transplantation; 2019 Nov; 103(11):2323-2328. PubMed ID: 30946215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease.
    Corey KE; Vuppalanchi R; Vos M; Kohli R; Molleston JP; Wilson L; Unalp-Arida A; Cummings OW; Lavine JE; Chalasani N;
    J Pediatr Gastroenterol Nutr; 2015 Mar; 60(3):360-7. PubMed ID: 25714579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review.
    Stahl EP; Dhindsa DS; Lee SK; Sandesara PB; Chalasani NP; Sperling LS
    J Am Coll Cardiol; 2019 Mar; 73(8):948-963. PubMed ID: 30819364
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Krag A; Karsdal MA; Nielsen MJ; Brockbank S; Cruwys S
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G410-G418. PubMed ID: 31905026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-alcoholic fatty liver disease: a metabolic burden promoting atherosclerosis.
    Zhang L; She ZG; Li H; Zhang XJ
    Clin Sci (Lond); 2020 Jul; 134(13):1775-1799. PubMed ID: 32677680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance.
    Grundy SM
    Clin Cornerstone; 2006; 8 Suppl 1():S21-7. PubMed ID: 16903166
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy.
    Sanches PL; de Piano A; Campos RM; Carnier J; de Mello MT; Elias N; Fonseca FA; Masquio DC; da Silva PL; Corgosinho FC; Tock L; Oyama LM; Tufik S; Dâmaso AR
    J Clin Lipidol; 2014; 8(3):265-72. PubMed ID: 24793347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis.
    Simon TG; Trejo MEP; Zeb I; Frazier-Wood AC; McClelland RL; Chung RT; Budoff MJ
    Metabolism; 2017 Oct; 75():1-5. PubMed ID: 28964324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.